Unknown

Dataset Information

0

Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase

ABSTRACT: Inhibition of soluble epoxide hydrolase improves efficacy of immunotherapy in murine cancer models.

ORGANISM(S): Mus musculus (mouse)

SUBMITTER:  

PROVIDER: S-BSST1321 | biostudies-other |

REPOSITORIES: biostudies-other

Json Xml

Similar Datasets

Unknown Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase.
| S-EPMC10873624 | biostudies-literature
Unknown Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression.
| S-EPMC11413684 | biostudies-literature
Unknown Enhancing cancer immunotherapy with nanomedicine.
| S-EPMC7536618 | biostudies-literature
Unknown Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation.
| S-EPMC8765052 | biostudies-literature
Unknown STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy.
| S-EPMC10484175 | biostudies-literature
Unknown Reprogramming Tumor-Associated Macrophages via Targeted NAT10 Inhibition to Enhance Colorectal Cancer Immunotherapy.
| S-EPMC12786336 | biostudies-literature
Unknown Dendritic cell-targeted liposomes for cancer immunotherapy via inhibition of aryl hydrocarbon receptor.
| S-EPMC12522837 | biostudies-literature
Unknown Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF-2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma.
| S-EPMC11670269 | biostudies-literature
Unknown Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
| S-EPMC5921900 | biostudies-literature
Unknown Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer.
| S-EPMC5784165 | biostudies-literature